The metabolic syndrome: diagnosis and treatment (Q36039083)

11 August 2017

1 reference

title

The metabolic syndrome: diagnosis and treatment (English)

1 reference

11 August 2017

1 reference

Franklin J Zieve

1

1 reference

11 August 2017

language of work or name

1 reference

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

6 Suppl 3

1 reference

11 August 2017

page(s)

S5-13

1 reference

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Myocardial infarction in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Prediction of Coronary Heart Disease Using Risk Factor Categories

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Ph

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

The weight reduction operation of choice: vertical banded gastroplasty or gastric bypass?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Effects of the amount and intensity of exercise on plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Preventing type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980093-0

7 January 2021

10.1016/S1098-3597(04)80093-0

Identifiers

DOI

1 reference

11 August 2017

1 reference